Tafamidis, sold under the brand names Vyndaqel and Vyndamax, is a transthyretin stabilizer used to slow disease progression in patients with transthyretin amyloidosis (ATTR). ATTR is a rare, progressive condition that leads to protein misfolding and organ damage, particularly affecting the heart and nerves. Tafamidis works by binding to transthyretin (TTR), stabilizing the protein, and preventing its aggregation into toxic amyloid deposits.
Parent: Tafamidis
![2-(3,4-dichlorophenyl)benzo[d]oxazole-6-carboxylic acid](https://veeprho.com/wp-content/uploads/2025/09/VE0025364-2-3-4-dichlorophenyl-benzo-d-oxazole-6-carboxylic-acid.png "2-(3,4-dichlorophenyl)benzo[d]oxazole-6-carboxylic acid")
Parent: Tafamidis
As with all pharmaceutical drugs, tafamidis can contain impurities that require monitoring and control to ensure safety and efficacy.
Related Substances
These are structurally similar compounds formed during synthesis or storage. They may include process-related impurities or intermediates used in drug formulation.
Degradation Products
Tafamidis may degrade due to temperature, humidity, or light exposure, leading to oxidation or hydrolysis byproducts.
Residual Solvents
Small amounts of organic solvents such as methanol, ethanol, or acetone may remain from the manufacturing process.
Heavy Metals and Elemental Impurities
Trace levels of heavy metals like lead, cadmium, and arsenic must be controlled to meet regulatory safety limits.
Analytical Techniques for Impurity Detection
High-Performance Liquid Chromatography (HPLC), Mass Spectrometry (MS), and Fourier Transform Infrared Spectroscopy (FT-IR) are commonly used to identify and quantify impurities in tafamidis formulations.
Tafamidis is used to treat transthyretin amyloidosis (ATTR), a condition where misfolded TTR proteins accumulate in organs, leading to heart failure and neuropathy.
Currently, there is no generic version of tafamidis available in Europe. The medication remains under patent protection.
Yes, Vyndaqel (tafamidis meglumine) is approved in Europe for treating ATTR amyloidosis, but Vyndamax (tafamidis free acid) is currently not approved in Europe.
Tafamidis has been shown to reduce disease progression and mortality in patients with ATTR cardiomyopathy. Clinical trials demonstrated a significant reduction in hospitalization rates and improved quality of life for patients receiving tafamidis compared to placebo.
